Ling Wang

机构：East Tennessee State University, Air Force Engineering University, Air Force Medical University · ORCID：0000-0002-0175-0933

发表论文 94 篇 · 总被引 2485 次 · h-index 26

代表论文

• Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial (2022 · EClinicalMedicine · 被引 23)
• Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication (2023 · Journal of Medical Virology · 被引 22)
• The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption (2024 · Frontiers in Genome Editing · 被引 21)
• Identifying serum metabolite biomarkers for autoimmune diseases: a two-sample mendelian randomization and meta-analysis (2024 · Frontiers in Immunology · 被引 17)
• Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial (2023 · Signal Transduction and Targeted Therapy · 被引 17)
• Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial (2025 · Gut · 被引 15)